$TRAX News
Last published 1w ago
- 1w agoTRAXFirst Tracks Biotherapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoTRAXFirst Tracks Biotherapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in
- 1w agoTRAXFirst Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAnnounced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease
- 3w agoTRAXFirst Tracks Biotherapeutics Announces $200 Million Private PlacementGlobeNewswireSAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in
- 1mo agoTRAXFirst Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac DiseaseGlobeNewswireANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptomsLS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on
- 1mo agoTRAXFirst Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026GlobeNewswireSAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in
- 2mo agoTRAXFirst Tracks Biotherapeutics Announces Participation in September Investor ConferencesGlobeNewswireSAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in
- 3mo agoTRAXFirst Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireCompleted enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients
- 5mo agoTRAXFirst Tracks Biotherapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in
- 6mo agoTRAXFirst Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireFirst Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO,
- 6mo agoTRAXFirst Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune DiseasesGlobeNewswireFirst Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runwayTrading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc.
- 7mo agoANABTRAXAnaptys Announces $100 Million Stock Repurchase Plan and Provides a Business UpdateGlobeNewswireAnaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with
- 8mo agoANABTRAXAnaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireSpin-off of biopharma operations into a public company to be called "First Tracks Biotherapeutics" on track for Q2 2026, potentially as early as late-AprilPhase 1b enrollment ongoing in celiac disease and trial cohort